Spinal Stimulation During Exercise in Heart Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02659202 |
Recruitment Status :
Recruiting
First Posted : January 20, 2016
Last Update Posted : February 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure | Device: Precision Spinal Cord Stimulator System | Not Applicable |
Forty Heart Failure (>18 yrs. of age) will be recruited. The study will include a total of 2 visits. All experiments will take place at the Mayo Clinic; at the outpatient radiology for MRI screening, the Charlton Clinical Research Unit (CRU) for surgical suite for spinal cord stimulation placement and the Saint Mary's Hospital Clinical Research Unit for clinical exercise laboratory for the exercise protocol and overnight stay.
Study visit 1 will include eligibility screening, consenting process, completion of a health questionnaire and performance of a peak oxygen consumption (VO2) test. Additionally, subjects will undergo a screening lumbar MRI to ensure that there are no anatomical anomalies in or around the epidural area consistent with standard clinical practice for epidural stimulator lead placement associated with chronic pain syndromes.
Study visit 2 will include an overnight stay in the Saint Mary's Hospital Clinical Research Unit. Patients will check in to the CRU in the morning of day 1, visit 2. Prior to placement of stimulating electrodes an international normalized ratio (INR) will be checked to ensure safe clotting. An anesthesiologist will place the electrodes in the lumbar/thoracic epidural space in a manner that is standard for the clinical placement of temporary electrodes in humans. The participants will then transfer to the clinical exercise laboratory to start the exercise protocol. Participants will rest 15 minutes prior to starting exercise. Exercise will take place on a vertical bike where they will perform a submaximal cycling exercise at 30% of peak work for 29 minutes. Thigh cuffs will be placed on thigh bilaterally and inflated intermittently to pressures of 80m mmHg. After the testing is complete, participants will return to their room in the Clinical Research Unit for the rest of the day and sty over night.
On day two of visit two, participants will repeat the testing from day one with new randomization to determine reliability of testing performed on day one. After the exercise on day two of visit two, the spinal cord stimulator leads and radial arterial catheter will be removed.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure |
Actual Study Start Date : | January 2016 |
Estimated Primary Completion Date : | December 1, 2022 |
Estimated Study Completion Date : | December 1, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Precision Spinal Cord Stimulator System
Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
|
Device: Precision Spinal Cord Stimulator System
The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit. |
- Mean Arterial Pressure [ Time Frame: 2 days ]This will allow for continuous real-time intra-arterial measurement of beat-to-beat blood pressure.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria, includes:
- Heart Failure patients with reduced ejection fraction:
- History of ischemic or idiopathic dilated cardiomyopathy (duration > 1yr.) stable for > 3mo and New York Heart Association Class I-III
- Not pacemaker dependent
- Body Mass Index ≤35
- Ejection Fraction < 40%
- Current nonsmokers with < 15 pack year history
- Able to exercise
Exclusion Criteria includes:
- History of cardiopulmonary disorders and dangerous arrhythmias
- Pregnant women
- Taking prescribed opioid medications or have had a fusion or laminectomy at L3 or above
- Patients with a recent drug-eluding stent
- History of spinal stenosis, lumbar radiculopathy, or peripheral neuropathy
- Must not currently be taking blood thinners or anticoagulant medications.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02659202
Contact: Briana Ziegler, BS | 507-255-7125 | ziegler.briana@mayo.edu |
United States, Minnesota | |
Mayo Clinic in Rochester | Recruiting |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Bruce Johnson, PhD | Mayo Clinic |
Responsible Party: | Bruce Johnson, PI, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT02659202 |
Other Study ID Numbers: |
14-002521 |
First Posted: | January 20, 2016 Key Record Dates |
Last Update Posted: | February 5, 2020 |
Last Verified: | February 2020 |
Exercise Heart Failure Blood Pressure |
Heart Failure Heart Diseases Cardiovascular Diseases |